知镜 Cognispect · 医学文献与研究工作台

Gamma-Glutamyl Transferase at the Crossroads of Cardiometabolic Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease.

Kozyk M, Strubchevska O, Strubchevska K, Kothari MM, Peterson SJ, Frishman WH, Aronow WS.
Cardiology in review · 2026-09-10 · PMID 42717298

文献摘要

Gamma-glutamyltransferase (GGT) is traditionally recognized as a sensitive marker of hepatobiliary dysfunction, but emerging evidence indicates that it is a key mediator between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiometabolic disease (CMD). This review explores the transformation of GGT from a passive diagnostic indicator into a systemic pro-oxidant driver and prognostic marker. GGT's role extends well beyond the gamma-glutamyl cycle. GGT triggers the catabolism of extracellular glutathione and, in the presence of transition metals, produces reactive oxygen species and initiates the development of atherosclerotic plaque. Clinical evidence significantly supports this mechanism. GGT levels correlate closely with markers of systemic inflammation and multiorgan dysfunction. Elevated GGT is associated with an increased risk of early-onset coronary artery disease and sustained cardiovascular mortality.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。